A Pilot Study Indicating Valuation of C‑Reactive Protein for Disease Outcome in Sickle Hemoglobin Patients of Central India
Evidences support the fact that sickle cell disease (SCD) is associated with a chronic inflammatory state characterized by haemolysis. C-reactive protein level (CRP) and white blood cell (WBC) count considered as biomarkers for inflammation. Also, elevation of serum total lactate dehydrogenase (LDH) levels are found to be associated with haemolysis, this makes LDH a nonspecific marker which has to be interpreted in a context of other markers of disease. The present study aims to assess the role of CRP levels, WBC counts, RBC counts, haemoglobin (Hb) concentrations and LDH levels in sickle hemoglobin (HbS) patients. Blood samples of 10 HbS patients (six females and four males) attending M.Y. Hospital, Indore during the period of Aug to Oct 2019 were screened for CRP, LDH and Hb levels and RBC and WBC counts using latex enhanced immune-turbidimetric assay, LDH optimize DGKC kinetic and differential automated hematology analyzer respectively. Data (mean ± SEM) was analyzed using Graphpad Prism software using Tukey’s multiple comparison post-hoc test. The mean Hb levels (7.73 ± 0.81 g/dl) and RBC counts (3.21 ± 0.53 million/µl) were found to be significantly decreased (p˂ 0.001 and 0.01 respectively) and mean WBC counts (15214.28 ± 1893.40 per mm3), CRP levels (85.73 ± 23.23 mg/l) and LDH levels (1334.00 ± 418.49 U/l) were found to be significantly increased (p˂ 0.0001, 0.01 and 0.01 respectively) in HbS patients in comparison with their respective controls. The variations in serum LDH and CRP levels are accompanied by changes in hematological parameters in HbS patients. These parameters may be considered as indicator of the severity of the disease.
Keywords: C-reactive protein, LDH, Sickle cell disease
2. Scott AA, Scott KD, Cultural therapeutic awareness and sickle cell anemia, J Black Psycology, 1999; 3:316-335.
3. Long KA, Thomas SB, Grubs RE, Getting EA, Krishnamurti L, Attitudes and beliefs of African-Americans towards genetics, genetic testing and sickle cell disease education and awareness, J Genetic Counsel, 2011; 20:572-592.
4. Centre for Disease Control and Prevention. Sickle cell disease (SCD). 2014. Retrieved April 1, 2014, from http:/www.cdc.gov/ncbddd/sickle cell/facts.html
5. Serjeant GR, Serjeant BE. Sickle cell disease. 1st ed. New York: Oxford University Press; 1992.
6. Lena M, Ndugwa CM, Ddungu H, Idro R, Foetal haemoglobin and disease severity in sickle cell anaemia patients in Kampala, Uganda, J Androl, 2012; 32:375-382.
7. Jain D, Lothe A, Colah R, Sickle cell Disease: Current challenges. J Hematol Thromboemol Dis, 2015; 3:6-10.
8. Fattoum S, Hemoglobinopathies in Tunisia. An updated reviewof the epidemiologic and molecular data, Tunis Med, 2006; 84:687-696.
9. Elshazly SA, Heiba NM, Abdelmageed WM, Plasma PTX3 levels in sickle cell disease patients, during vaso-occlusion and acute chest syndrome (data from Saudi population), Hematology, 2014; 19:52-59.
10. Adisa OA, Hu Y, Ghosh S, Aryee D, Osunkwo I, Ofori-Acquah SF, Association between plasma free haem and incidence of vaso-occlusive episodes and acute chest syndrome in children with sickle cell disease, Br J Haematol, 2013; 162:702-705.
11. Ruffieux N, Njamnshi AK, Wonkam A, Hauert CA, Chanal J, Verdon V et al., Association between biological markers of sickle cell disease and cognitive functioning amongst Cameroonian children, Child Neuropsychol, 2013; 19:143-160.
12. Emokpae MA, Uadia PO, Gadzama AA, Correlation of oxidative stress and inflammatory markers with the severity of sickle cell nephropathy, Ann Afr Med, 2010; 9:141-146.
13. Van Beers EJ, Yang Y, Raghavachari N, Tian X, Allen DT, Nichols JS et al., Iron, inflammation and early death in adults with sickle cell disease, Circ Res, 2015; 116:298-306.
14. Nongbri S, Rudy L, Verma HK, Lakkakula Bhaskar V.K.S., Patra PK, Presence of atypical beta globin (HBB) gene cluster haplotypes in sickle cell anemia patients of India, Rev Bras Hematol Hemoter, 2017; 39:180–182.
15. Rees DC, Gibson JS, Biomarkers in sickle cell disease, British J Haematol, 2011; 156:433–444.
16. De FL, Mura P, Schweiger V, Vencato E, Quaglia FM, Delmonte L et al., Fentanyl buccal tablet: A new breakthrough pain medication in early management of severe vaso-occlusive crisis in sickle cell disease, Pain Pract, 2015; 26:1-10.
17. Bandeira IC, Rocha LB, Barbosa MC, Elias DB, Querioz JA, Freitas MV et al., Chronic inflammatory state in sickle cell anemia patients is associated with HBB(*)S haplotype, Cytokine, 2014; 65:210-217.
18. Mohammed FA, Mahdi N, Sater MA, Al-Ola K, Almawi WY, The relation of C-reactive protein to vasoocclusive crisis in children with sickle cell disease, Blood Cells Mol Dis, 2010; 45:293-296.
19. Schnog JB, Mac Gillavry MR, van Zanten AP, Meijers JC, Rojer RA, Duits AJ et al., Protein C and S and inflammation in sickle cell disease, Am J Hematol, 2004; 76:26-32.
20. Misialek JR, Bekwelem W, Chen LY, Loehr LR, Agarwal SK, Soliman EZ et al., Association of white blood cell count and differential with the incidence of atrial fibrillation: The atherosclerosis risk in communities (ARIC) study,PLoS One, 2015; 10:e0136219.
21. Platt OS, Thorington BD, Brambilla DJ et al., Pain in sickle cell disease. Rates and risk factors, New Eng J Med, 1991; 325:11–16.
22. Taylor, JG, Nolan VG, Mendelsohn L, Kato GJ, Gladwin MT, Steinberg MH, Chronic hyper-hemolysis in sickle cell anemia: association of vascular complication and mortality with less frequent vasoocclusive pain, PLos One, 2008; 3:e2095.
23. Mikobi TM, Lukusa Tshilobo P, Aloni MN, Mvumbi Lelo G, Akilimali PZ, Muyembe-Tamfum JJ, et al., Correlation between the lactate dehydrogenase levels with laboratory variables in the clinical severity of sickle cell anemia in Congolese patients, PLoS One, 2015; 10;e0123568.
24. Jain D, Lothe A, Colah R, sickle cell disease: Current challenges. J Hematology Thromboemol Dis, 2015; 3:6.
25. Connes P, Lamarre Y, Waltz X, Ballas SK, Lemonne N, Etienne-Julan M et al., Haemolysis and abnormal haemorheology in sickle cell anaemia, Br J Haematol, 2014; 24:1-6.
26. Krishnan S, Setty Y, Betal SG, Vijender V, Rao K, Dampier C et al., Increased levels of the inflammatory biomarker C-reactive protein at baseline are associated with childhood sickle cell vasocclusive crises, Br J Haematol, 2010; 148:797-804.
27. Kasschau MR, Barabino GA, Bridges KR, Golan DE, Adhesion of sickle neutrophils and erythrocytes to fibronectin, Blood, 1996; 87:771–780.
28. Okocha C, Manafa P, Ozomba J, Ulasi T, Chukwuma G, Aneke J, C-reactive protein and disease outcome in Nigerian sickle cell disease patients, Ann Med Health Sci Res, 2014; 4:701-705.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).